The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Ethical and legal issues in psychedelic harm reduction and integration therapy
Open accessAbstract
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pressing need for novel therapeutic options for treatmentresistant psychiatric disorders is leading many patients to selfadminister this drug, rather than waiting for further evidence of efficacy, legal medical, and protected access. 98”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [98]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“While previous decades of psychedelic research have focused on a wide array of psychological problems using many different psychedelic substances, modern research has demonstrated the strongest evidence for psychedelic-assisted therapy in the treatment of post-traumatic stress disorder (PTSD) [18], depression [19], en…”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., Torre, F. L., Fabiani, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01526 · Cited by 616
Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T. E., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 610
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 1×
“Traditional or "classic" psychedelics are serotonergic agonists that include lysergic acid diethylamide (LSD), mescaline, dimethyltryptamine (DMT), and psilocybin [3].”
Background
Research works printed but not linked: 4
- Tanne JH. Humphry Osmond. BMJ. 2014;328(7441):713.
- United Nations Office on Drugs and Crime. Amphetamine-type stimulants: a global review. 1996.
- Ekman Schenberg E. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733. · DOI
- Carlin SC, Scheld S. MDMA-assisted psychotherapy code of ethics. MAPS Bull Spring. 2019;29(1):10.
Cited by
Sorted by citations
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 128
The neuroplastic brain: current breakthroughs and emerging frontiers
Gazerani, P. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149643 · Cited by 153
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Barber, G., & Dike, C. C. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220525 · Cited by 73
Rosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 68
Lutkajtis, A., & Evans, J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00232 · Cited by 67
Kopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 67
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 70
Earleywine, M., Low, F., Lau, C., & Leo, J. A. D. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221085800 · Cited by 64
Belouin, S. J., Averill, L. A., Henningfield, J. E., Xenakis, S. N., Donato, I., Grob, C. S., Berger, A., Magar, V., Danforth, A. L., & Anderson, B. T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109214 · Cited by 54
Counselors’ attitudes toward psychedelics and their use in therapy
Hearn, B., Brubaker, M. D., & Richardson, G. B. (2022) · Journal of Counseling & Development · doi:10.1002/jcad.12429 · Cited by 52
Naturalistic Psychedelic Use: A World Apart from Clinical Care
Glynos, N. G., Fields, C. W., Barron, J., Herberholz, M., Kruger, D. J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2108356 · Cited by 51
The need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 44
Wolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 40
Psilocybin’s effects on cognition and creativity: A scoping review
Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia‐Romeu, A., & García-Barrera, M. A. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179801 · Cited by 38
Palmer, M., & Maynard, O. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00662-0 · Cited by 38
Predictors of Psychedelic Experience: A Thematic Analysis
McCartney, A., McGovern, H. T., & Foe, A. D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2129885 · Cited by 38
Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30
Enhancing equity-oriented care in psychedelic medicine: Utilizing the EQUIP framework
Rea, K., & Wallace, B. B. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103429 · Cited by 32
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29
Kucsera, A., Suppes, T. M., & Haug, N. A. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2880 · Cited by 28
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. W. (2023) · Ochsner Journal · doi:10.31486/toj.23.0076 · Cited by 32
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 30
Psilocybin in Palliative Care: An Update
Whinkin, E., Opalka, M., Watters, C., Jaffe, A., & Aggarwal, S. K. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00383-7 · Cited by 33
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D. J., & Spriggs, M. J. (2023) · Neuroethics · doi:10.1007/s12152-023-09536-z · Cited by 31
Williams, M. L., Korevaar, D., Harvey, R., Fitzgerald, P. B., Liknaitzky, P., O'Carroll, S., Puspanathan, P., Ross, M., Strauss, N. H. M., & Bennett–Levy, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.737738 · Cited by 26
Greń, J., Tylš, F., Lasocik, M., & Kiraly, C. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1054692 · Cited by 29
The illusion of knowledge in the emerging field of psychedelic research
Oña, G., Kohek, M., & Bouso, J. C. (2022) · New Ideas in Psychology · doi:10.1016/j.newideapsych.2022.100967 · Cited by 24
Social identity processes as a vehicle for therapeutic success in psychedelic treatment
Newson, M., Haslam, S. A., Haslam, C., Cruwys, T., & Roseman, L. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00302-5 · Cited by 21
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
ARC: a framework for access, reciprocity and conduct in psychedelic therapies
Spriggs, M. J., Murphy-Beiner, A., Murphy, R., Bornemann, J., Thurgur, H., & Schlag, A. K. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1119115 · Cited by 16
Korthuis, P. T., Hoffman, K. A., Wilson‐Poe, A. R., Luoma, J. B., Bazinet, A. D., Pertl, K., Morgan, D. L., Cook, R., Bielavitz, S., Myers, R., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241257839 · Cited by 16
Self-citationPsychedelic public health: State of the field and implications for equity
Kuiper, H., Alley, C., Harris, Z., Rauch, C. K., Robbins, M., Rodríguez, P. G., Tomczak, P., Urrutia, J., & Magar, V. (2024) · Social Science & Medicine · doi:10.1016/j.socscimed.2024.117134 · Cited by 16
Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review
Caporuscio, C., Poppe, C. J., Gieselmann, A., & Repantis, D. (2025) · Psychological Medicine · doi:10.1017/s0033291725101761 · Cited by 17
Azevedo, N., da Silva, M. O., & Madeira, L. (2023) · Philosophies · doi:10.3390/philosophies8050076 · Cited by 15
Key competencies for psychedelic treatment in real-world mental health care settings
Wolff, M., Rutrecht, H. M., Gründer, G., Jungaberle, A., & Jungaberle, H. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.09.003 · Cited by 15
Psychedelics and the treatment of eating disorders: considerations for future research and practice
Lacroix, E., Fatur, K., Hay, P., Touyz, S. W., & Keshen, A. R. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01125-6 · Cited by 13
Pattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Mystical experiences without mysticism: An argument for mystical fictionalism in psychedelics
Armour‐Garb, B., & Earleywine, M. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00207 · Cited by 12
Bear, D., Hosker-Field, A. M., Westall, K., D'Alessio, H., & Cresswell, M. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104514 · Cited by 11
Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study
Žuljević, M. F., Hren, D., Storman, D., Kaliterna, M., & Duplančić, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-69688-7 · Cited by 11
Psychedelic-related deaths in England, Wales and Northern Ireland (1997–2022)
Kopra, E. I., Penttinen, J., Rucker, J., & Copeland, C. S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111177 · Cited by 12
Focusing on the negative: cases of long-term negative psychological responses to psychedelicsPreprint
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · doi:10.31234/osf.io/yzmcj · Cited by 11
Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
Bellman, V. (2024) · Cancers · doi:10.3390/cancers16091702 · Cited by 11
Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R. L., Ching, T. H. W., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0019 · Cited by 12
Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002268 · Cited by 13
Modlin, N. L., McPhee, T., Zazon, N., Sarang, M., Hignett, R., Pick, S., Cleare, A. J., Williamson, V., & Rucker, J. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0027 · Cited by 10
The Birth of the Psychedelic Industry: Capitalising on the Psychedelic Renaissance
Yoo, M., & Sakopoulos, S. (2024) · Future Humanities · doi:10.1002/fhu2.70004 · Cited by 9
Adams, D. R., ALLEN, H. L., Nicol, G. E., & Cabassa, L. J. (2024) · Translational Behavioral Medicine · doi:10.1093/tbm/ibae053 · Cited by 11
Regulatory Challenges of Integrating Psychedelics into Mental Health Sector
Soylemez, K. K., de Boo, E. M., & Lusher, J. M. (2025) · Psychoactives · doi:10.3390/psychoactives4020011 · Cited by 10
Avanceña, A. L. V., Vuong, L., Kahn, J. G., & Marseille, E. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03556-4 · Cited by 9
Caraccio, M., Cheung, K., Mann, S. P., Bruce, L., Jacobs, E., Villiger, D., Sandbrink, J. D., Register, C., Hannikainen, I. R., Høeg, M. L., et al. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2532761 · Cited by 8
Argyri, E. K., Krecké, J., Robinson, O. C., Evans, J., Skragge, M., & Morgan, C. J. A. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01347-0 · Cited by 8
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
Stein, C. A., Penn, A., Hope, S., Dorsen, C. G., & Mangini, M. (2022) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13371 · Cited by 9
Dames, S., Watler, C., Kryskow, P., Allard, P., Gagnon, M., Taylor, W., & Tsang, V. W. L. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0004 · Cited by 8
Smith, C. L., Sackett, N. B., Stark, B. C., Dinh, V., Romesburg, E. W., & Roll, J. M. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0074 · Cited by 7
Ensuring psychedelic treatments and research do not leave anyone behind
Simon, M. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01710-4 · Cited by 7
Fernandes-Nascimento, M. H., Negrão, A. B., Viana-Ferreira, K., Chaves, B. R., & Wang, Y. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2276230 · Cited by 7
Ramos, L., & Vicente, S. (2024) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2024.2363343 · Cited by 6
Katragunta, K., Avula, B., Chittiboyina, A. G., Lata, H., & Khan, I. A. (2024) · International journal of medicinal mushrooms · doi:10.1615/intjmedmushrooms.2024056373 · Cited by 6
Baldo, B. A. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03765-8 · Cited by 6
Conceptualizing your new reality: Should philosophers play a role in psychedelic-assisted therapy?
Quasti, C., & Sisti, D. A. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00355 · Cited by 7
Masse-Grenier, M., Chang, S.-L., Bélanger, A., Stephan, J.-F., Hébert, J., Deschamps, P., Plourde, L., Provost, F., Farzin, H., Fallu, J., et al. (2024) · Palliative & Supportive Care · doi:10.1017/s1478951524001494 · Cited by 6
Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
McCartney, A., McGovern, H. T., & Foe, A. D. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00211 · Cited by 13
Garel, N., Plourde, L., Greenway, K. T., & Dorval, M. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00446-y · Cited by 5
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain
Frautschi, P. C., Singh, A. P., Stowe, N. A., & Yu, J. J. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8118 · Cited by 5
Marie, S. (2024) · Anthropology of Consciousness · doi:10.1111/anoc.12226 · Cited by 5
Harm reduction practises for users of psychedelic drugs: a scoping review
Dutton, C., North, E., Tie, Y. C., Oliva, J., & Skeffington, P. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01264-2 · Cited by 6
Burt, I. (2023) · Journal of Creativity in Mental Health · doi:10.1080/15401383.2023.2237868 · Cited by 4
Barber, M., Gardner, J., Liknaitzky, P., & Carter, A. (2024) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12545 · Cited by 6
Lutkajtis, A. (2022) · International Journal for the Study of New Religions · doi:10.1558/ijsnr.20152 · Cited by 4
Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin
Bhuiya, N. M. M. A., Jacobs, R. J., Wang, K., Sun, Y., Nava, B., Sampiere, L., Yerubandi, A., & Caballero, J. (2023) · Cureus · doi:10.7759/cureus.45169 · Cited by 4
Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns
Cheung, K., Brodie, M., Chang, S.-L., Deschamps, P., Fallu, J., Farzin, H., Hébert, J., Stephan, J.-F., Dorval, M., Joly, Y., et al. (2025) · The Journal of Law Medicine & Ethics · doi:10.1017/jme.2025.10109 · Cited by 3
McHerron, D., Barber, M., Ham, R., Liknaitzky, P., Carter, A., & Gardner, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251377191 · Cited by 4
Chaplains in Psychedelic Assisted Therapy: Rationale and Competencies
Lewis, S. P., Clark‐Soles, J., Mayorga, O., Sawyer, S. K., Slavet, E., Vidt, B. J., Shanti, S., Wiggins, R., Willis, K., Frey, J., et al. (2026) · Journal of Religion and Health · doi:10.1007/s10943-026-02591-9 · Cited by 4
Palmer, M., & Maynard, O. (2022) · Research Square · doi:10.21203/rs.3.rs-1457443/v1 · Cited by 4
Mota, P. M. P. C., Encantado, J., Carvalho, L., Cunha, C., Garcia‐Romeu, A., Johnson, M. W., & Teixeira, P. J. (2025) · Acta Médica Portuguesa · doi:10.20344/amp.22815 · Cited by 2
Examining Volunteer Bias in Psychedelic Research
Gomez, S. G., Low, F., & Earleywine, M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2570936 · Cited by 2
Kruger, D. J., Mersereau, G., Sullivan, A., Barron, J., Herberholz, M., Pouyan, N., Aday, J. S., & Boehnke, K. F. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01337-2 · Cited by 4
Carlson, L. E., Richardson, H., Shore, R., Albertyn, C. P., Balneaves, L. G., Bates, A. T., Burnell, M. J., Chochinov, H. M., Clements, D., Deleemans, J. M., et al. (2025) · Current Oncology · doi:10.3390/curroncol33010007 · Cited by 2
The modern clinical use of hallucinogens. What can we learn from the natural product research?
Oña, G., Kohek, M., & Bouso, J. C. (2022) · Natural Product Research · doi:10.1080/14786419.2022.2103697 · Cited by 2
Al-Imam, A., Motyka, M. A., & Michalak, M. (2024) · European Journal of Investigation in Health Psychology and Education · doi:10.3390/ejihpe14030038 · Cited by 2
Koning, E., Chaves, C., Kirkpatrick, R. H., & Brietzke, E. M. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01185-8 · Cited by 2
Halperin, D., On, T. B., Tadmor, N., Simon, A. M., Cherniak, A. D., & Simon, G. (2025) · Future Humanities · doi:10.1002/fhu2.70009 · Cited by 2
Singh, A. N. A., & de Assis, G. L. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00368-7 · Cited by 3
Sharma, K., & Makhija, T. K. (2024) · International Journal of All Research Education & Scientific Methods · doi:10.56025/ijaresm.2024.1204243732 · Cited by 1
Integrating Psychedelics into Groupwork: A Culturally Responsive Model for the Counseling Profession
Burt, I. (2024) · Psychoactives · doi:10.3390/psychoactives3030022 · Cited by 1
Social Worker Attitudes towards Psychedelics
Nowakowski-Sims, E., & Holzworth, J. (2025) · Clinical Social Work Journal · doi:10.1007/s10615-025-00988-9 · Cited by 2
Arnison, C., Egan, R., & Shaver, J. H. (2025) · Kōtuitui New Zealand Journal of Social Sciences Online · doi:10.1080/1177083x.2025.2467035 · Cited by 1
Plant-based theatre: Drama therapy assists psychedelic-assisted therapy
Alters, B. (2025) · Drama Therapy Review · doi:10.1386/dtr_00159_1 · Cited by 1
The Use of Psychedelics in Couples Therapy
Groveman, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-90006-8_2 · Cited by 1
Khan, Z., Weaver, S., Dando, R. V., Schlag, A. K., Neill, J. C., & Wainwright, V. (2026) · Qualitative Health Research · doi:10.1177/10497323261419338 · Cited by 1
Psychedelics, Harm Reduction, and Ethical Care
Sarno, M. (2026) · Journal of Health Service Psychology · doi:10.1007/s42843-025-00144-4 · Cited by 1
Should People With a History of Psychosis Be Included in Psychedelic Research?
Rajwani, K. (2026) · Canadian Journal of Bioethics · doi:10.7202/1124213ar · Cited by 1
Castellano-Ramírez, D., Hernández‐Álvarez, E., Borkel, L. F., Rojas‐Hernández, J., Hernández, D. J. Q., & Henríquez‐Hernández, L. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344698 · Cited by 1
Psychedelic Art Therapy: The Intersection of Psychedelics, Creativity, and Art Therapy
Wilkinson, R. A., & Gursky, A. B. (2026) · Art Therapy · doi:10.1080/07421656.2026.2641876 · Cited by 1
Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians
Beichmann, K., Catzeflis, P., Aicher, H., Seragnoli, F., Calder, A. E., Amrani, A., & Hasler, G. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261448745 · Cited by 1
Legal and regulatory compliance in digital twin-enabled healthcare
Chaudhary, A., & Malik, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45282-6.00008-2 · Cited by 1
THE SEROTONIN 5-HT2ARECEPTOR AS AN EVOLVING NEUROTHERAPEUTIC TARGET
Bolinger, A. A., Anastasio, N. C., Cunningham, K. A., & Zhou, J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch03 · Cited by 1
Protecting Patient Autonomy in Psychedelic-Assisted Psychotherapy: A Nursing Ethics Perspective
Tustison, J., Niemi, C. A., & Choi, K. R. (2025) · Issues in Mental Health Nursing · doi:10.1080/01612840.2025.2514624 · Cited by 1
Psychedelic therapy for body dysmorphic disorder
Johnson, S., & Letheby, C. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00200 · Cited by 1
Metadata
- Authors
- Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F.
- Affiliations
- Adler University (US)
- Corresponding author
- Pilecki, Brian
- Venue
- Harm Reduction Journal
- Published
- 2021-04-07
- Volume
- 18
- Issue
- 1
- Pages
- 40-40
- ISSN
- 1477-7517 (ISSN-L)
- PMC
- PMC8028769
- OpenAlex
- W3149986569
- Cited by
- 141
- References
- 69
- Citations by year
- 2026: 25 · 2025: 34 · 2024: 34 · 2023: 24 · 2022: 21 · 2021: 3
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Harm Reduction Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- None
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Clinical Psychology › Counseling Practices and Supervision
- Keywords
- psychedelic therapy, harm reduction, psychedelic use, therapist ethics, legal issues, prohibited substances, clinical scenarios
- MeSH terms
- Behavior Therapy, Hallucinogens, Humans, Morals, Psychotherapy, Harm Reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
